Novo Nordisk funds API manufacturing with €726m
Novo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 287 entries already.
Entries by Uta Mommert
SOTIO licences first cancer ADC from LegoChem Biosciences
SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.
CatalYm GmbH raises €50m to push visugromab development
Munich-based immunooncology specialist CatalYm GmbH wants to use €50m from a Series C financing round to advance its anti-GDF15 antibody to Phase II development.
Cultimate Foods UG raises €700.000 in pre-seed financing
Cellular agriculture company Cultimate Foods UG has got a pre-seed funding led by Big Idea Ventures, ProVeg International and Realum.cloud.
Cradle BV bags €5.4m in seed financing
Biotech start-up Cradle BV has raised €5.4m in seed financing to design cell-factories with AI and scale bioprocesses much faster and cheaper.
Standing Ovation inks exlusive partnership with Bel Group
Microbial casein maker Standing Ovation SA has inked an exklusive collaboration with Bel Group, one of France’s biggest cheese-makers to bring its vegan cheese to the market.
Novo Nordisk Foundation funds Plant2Food with €27m
Danish Novo Nordisk Foundation has invested in Plant2Food, a new open innovation hub for researchers and companies to develop plant-based foods.
Jolt Capital boosts BC Platforms with $20m
Jolt Capital contributed $20m to the BC Platforms’ data footprint expansion on November 8th.
Novadip Biosciences SA raises €40m
Wth a Series B €40m financing, Novadip Biosciences SA has raised investements to a total of €88m. It will use the proceeds to push two single-use cell therapies designed to accelerate healing.
Benefits of booster campaigns questionable
Three small-scale studies hinted at new COVID-19 vaccination boosters not significantly enhancing the immune response to Omicron variant.